

tissue level. It can be utilized in a variety of patient populations and conditions. For example, the probe can be used to monitor the local biochemical milieu in soft tissue and organ systems to provide insights into the pathophysiology of musculoskeletal, neuromuscular, rheumatic, gastrointestinal, renal, cardiovascular and endocrinologic diseases, cancers, dermatological conditions, and pediatric disorders, especially in premature newborns.

The probe is made from a small-bore (32 gauge) needle, whose probe surface has been fashioned to permit near trauma-less entry, containing both a fluid delivery and recovery tube within the bore. A molecular exchange membrane is positioned about 200 microns from the tip. Fluid flows across the membrane removing diffused molecules to a collection device. The rounded tip of the needle is designed to cause minimal tissue damage while allowing investigations to be performed on local tissue fluids. Additionally, this device allows simultaneous delivery of small concentrations of drug. In summary, this unique apparatus provides a minimally invasive means for sampling biological fluids in any human or animal organ or tissue and for *in-situ* drug-delivery, in continuous or incremental dosing, of extremely small doses.

**Applications:** Measurement of bioavailable substances in organs and soft tissues; Localized drug delivery vehicle; Measurement of tissue drug levels.

**Market:** Drug discovery; Tissue/fluid sampling; Pain management.

**Inventors:** Jay Shah (NIHCC), Terence Martyn Phillips (ORS), Jerome V. Danoff (NIHCC), Lynn Gerber (NIHCC).

**Publication:** JP Shah, TM Phillips, JV Danoff, LH Gerber. An *in vivo* microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. *J Appl Physiol.* 2005 Nov; 99(5):1977–1984. Epub 2005 Jul 21.

**Patent Status:** U.S. Provisional Application No. 60/795,176 filed 27 Apr 2006 (HHS Reference No. E–024–2006/0–US–01).

**Licensing Contact:** Michael A. Shmilovich, Esq.; 301/435–5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

#### **Fluorescent Intracellular Calcium Indicators**

**Description of Technology:** Calcium is a key element in the regulation of many cellular processes, including muscle contraction, hormone excretion from gland cells, neurotransmitter release from nerve synapses, and the regulation

of cellular metabolism. Elevated calcium levels are found in a number of diseases.

The present invention relates to chromophoric or fluorescent dye calcium indicators that are superior for measurement of high concentrations of calcium ions due to their high dissociation constants. As a result of the high calcium ion dissociation constants, the perturbation resulting from introducing the indicator into the cell is greatly reduced. These calcium ion indicators can be measured by various techniques including 19F NMR spectroscopy, flow cytometry, and quantitative fluorescence techniques, and are useful for measuring calcium levels within the cytosol or within cellular organelles.

**Application:** Research tool for quantifying intracellular calcium concentrations.

**Inventors:** Robert E. London, Louis A. Levy, and Elizabeth Murphy (NIEHS).

**Patent Status:** U.S. Patent Application No. 08/175,590 filed 30 Dec 1993, which issued as U.S. Patent No. 5,516,911 on 14 May 1996 (HHS Reference No. E–015–1993/0–US–01).

**Licensing Status:** Available for nonexclusive licensing.

**Licensing Contact:** Tara Kirby, PhD; 301/435–4426; [tarak@mail.nih.gov](mailto:tarak@mail.nih.gov).

**Collaborative Research Opportunity:** The NIEHS Laboratory of Structural Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Dr. Robert London at 919/541–4879 or [london@niehs.nih.gov](mailto:london@niehs.nih.gov) for more information.

Dated: March 19, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7–5676 Filed 3–27–07; 8:45 am]

**BILLING CODE 4140–01–P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Center on Minority Health and Health Disparities; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Center on Minority Health and Health Disparities Special Emphasis Panel, LRP for Health Disparities and Clinical Research-Panel B.

**Date:** April 29, 2007.

**Time:** 9 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6707 Democracy Blvd./Suite 800, Bethesda, MD 20892, (Virtual Meeting).

**Contact Person:** Lorrta Watson, PhD, National Center on Minority Health, and Health Disparities, National Institutes of Health, 6707 Democracy Blvd., Suite 800, Bethesda, MD 20892–5465, (301) 402–1366, [watsonl@ncmhd.nih.gov](mailto:watsonl@ncmhd.nih.gov).

**Name of Committee:** National Center on Minority Health and Health Disparities Special Emphasis Panel, NCMHD Conference Grant Application (R13) Review.

**Date:** May 1, 2007.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).

**Contact Person:** Robert Netter, MD, Scientific Review Administrator, National Institute on Minority Health, and Health Disparities, 6707 Democracy Blvd., Suite 800, Bethesda, MD 20892, 301–496–3996.

Dated: March 21, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07–1516 Filed 3–27–07; 8:45 am]

**BILLING CODE 4140–01–M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Eye Institute, Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose